ArticleNeuropsychiatric disease and treatment2017
Efficacy and safety of
Article in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Polyphenols and Neurodegenerative Diseases: Knowledge-Mining Insights, Mechanistic Evidence, and Emerging Nutritional Applications.Nutrients · 2026Review
- Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study.JMIR research protocols · 2025Article
- NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer's Disease.Biomedicines · 2023Review
- Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update.Current neuropharmacology · 2023Review
- Natural Product Co-Metabolism and the Microbiota-Gut-Brain Axis in Age-Related Diseases.Life (Basel, Switzerland) · 2022Review
- Review
- A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia.Aging medicine (Milton (N.S.W)) · 2022Article
- Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia.Clinical drug investigation · 2022Article
- Article
- ESO Guideline on covert cerebral small vessel disease.European stroke journal · 2021Article
- Neuroprotection: Targeting Multiple Pathways by Naturally Occurring Phytochemicals.Biomedicines · 2020Review
- Clinical practice guideline for cognitive impairment of cerebral small vessel disease.Aging medicine (Milton (N.S.W)) · 2019Article
- Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence.Oxidative medicine and cellular longevity · 2019Review
- Possibilities of Dementia Prevention - It is Never Too Early to Start.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of
methodsA total of 90 patients (aged 67.1±8.0 years; 59 women) were randomly allocated (1:1:1) to receive
resultsAt the end of 6-month study period,
conclusionAccording to our results,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.